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Abstract  
Type 2 diabetes and cardiovascular disease are complex disorders involving metabolic and 
inflammatory mechanisms. Here we investigated whether sCD93, a group XIV c-type lectin of 
the endosialin family, plays a role in metabolic dysregulation or carotid intima-media thickness 
(IMT). Whilst no association was observed between sCD93 and IMT, sCD93 levels were 
significantly lower in subjects with type 2 diabetes (n=901, mean±sd: 156.6±40.0ng/mL), 
compared to those without (n=2470, 164.1±44.8ng/mL, p<0.0001). Genetic variants associated 
with diabetes risk (DIAGRAM consortium) did not influence sCD93 levels (individually or 
combined in a SNP score). In a prospective cohort, lower sCD93 levels preceded diabetes 
development. Consistent with this, a cd93-deficient mouse model (in addition to apoe 
deficiency) demonstrated no difference in atherosclerotic lesion development compared to 
apoe-/- cd93-sufficient littermates. However, cd93-deficient mice showed impaired glucose 
clearance and insulin sensitivity (compared to littermate controls) after a high fat diet. 
Expression of cd93 was observed in pancreatic islets, and leaky vessels were apparent in cd93-
deficient pancreases. We further demonstrated that stress-induced release of sCD93 is impaired 
by hyper-glycaemia. Therefore, we propose CD93 as an important component in 
glucometabolic regulation.  
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Introduction 
Subjects with type 2 diabetes have 2 to 4-fold greater risk for developing cardiovascular disease 
(CVD) than those without. Preventative strategies targeting CVD have shown little progress in 
subjects with type 2 diabetes, despite their efficacy in subjects without diabetes. Although 
complete understanding of mechanisms leading to CVD is lacking, a combination of metabolic 
dysregulation and inflammatory pathways are important contributors. Therefore, elucidation of 
pathways linking metabolic dysregulation and inflammation could pinpoint potential 
therapeutic targets for reducing CVD, especially in subjects with type 2 diabetes.  
CD93 is a group XIV c-type lectin belonging to the endosialin family, originally described as 
a component of the complement system (1). CD93 is composed of a cytoplasmic tail containing 
a PDZ binding domain (2), a transmembrane domain containing metalloproteinase sites, an 
extracellular region containing a mucin-like domain that is highly glycosylated, 5 EGF domains 
(4 in mice) and a unique C-type lectin domain. CD93 is predominantly expressed on endothelial 
cells, but also in innate immune cells such as neutrophils and monocytes as well as in 
megakaryocytes (3). In response to certain inflammatory molecules, the transmembrane CD93 
is cleaved and the extracellular segment is released into the circulation as soluble CD93 
(sCD93) (4; 5). It is still unknown whether the released sCD93 has a distinct function, or 
whether release of this fragment is merely to enable the intra-cellular remnant to respond to the 
cellular stress. Described as a factor involved in removal of apoptotic bodies, CD93 has also 
been involved in B cell maturation and Natural Killer T cell (iNKT cell) survival (6). EGF 
domains are believed to be involved in angiogenesis (7) and the moesin-binding domain (8) is 
required for endothelial cell-cell interactions (9). 
Regarding metabolism and CVD, CD93 is a plausible candidate in the mouse non-obese 
diabetes Idd13 locus (10), and we have previously shown that reduced levels of circulating 
sCD93 are associated with increased risk of myocardial infarction (MI) (11). More recently, the 
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CD93 gene has been identified as a potential regulator of pathways common to both type 2 
diabetes and CVD (12). Interestingly, CD93 expression is up-regulated by conditions relevant 
to diabetes or its complications, for example flow-related shear stress (13) due to endothelial 
dysfunction; during the development of new but leaky blood vessels (14) as observed in 
retinopathy; during ischemia-related inflammation of cerebral vascular endothelium (15) thus 
reflecting MI. 
Here we investigated sCD93 for effects on markers of metabolic dysregulation and early 
cardiovascular disease in human cohorts and in a mouse model with a genetic deficiency in 
sCD93. We further examined the mechanisms by which sCD93 acts.  
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Research Design and Methods 
Discovery analyses: IMPROVE 
The IMPROVE cohort has previously been described (16; 17). Briefly, subjects with at least 3 
established CVD risk factors without symptoms or history of coronary artery disease were 
enrolled from 7 European centres (at latitudes ranging from 43 to 62° North). Medical history, 
anthropometric measurements and blood samples were obtained at baseline and standard 
biochemical phenotyping was performed. Blood samples were stored at -80⁰C. Extensive 
carotid intima-media thickness (IMT) phenotyping was performed by ultrasound at baseline, 
as well as 15 and 30 months after enrolment (16; 17).  Approval was granted by the regional 
ethics committee for each recruitment centre and written informed consent was provided by 
all participants. Type 2 diabetes was defined as diagnosis, anti-diabetic medication or fasting 
glucose ≥7mmol/L. Soluble CD93 was measured using the Mesoscale platform, using the 
previously validated ELISA antibodies (11) and SECTOR Imager 2400. Characteristics of the 
cohort are presented in Table 1. 
IMPROVE Genotyping 
Reported type 2 diabetes risk-associated SNPs (18) were genotyped in the IMPROVE cohort 
using the Illumina Metabochip (19) and Immunochip (20) platforms. Genotyping was 
conducted at the SNP&SEQ Technology Platform, Uppsala University, Sweden and standard 
quality control was conducted; Subject exclusions: low call rate (<95%), cryptic relatedness 
or ambiguous sex. SNPs exclusions; failing call rate (<95%) or Hardy–Weinberg equilibrium 
(p<5*10-6) thresholds. After quality control, multi-dimensional scaling (MDS) components 
were calculated using PLINK (21) with default settings. The first MDS component 
demonstrates strong correlations with latitude of recruitment centre (Spearmans rank Rho 
0.935 p<0.0001 and Rho 0.946 p<0.0001 for subjects without and with type 2 diabetes 
respectively).  
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Statistical analyses: IMPROVE Epidemiology 
The trend test for ordered groups was used to assess an effect of recruitment centre latitude. 
Differences in sCD93 levels between men/women and subjects with/without diabetes were 
assessed by T-test. Associations between sCD93 levels and established risk factors were 
assessed by Spearman rank correlation coefficients. Skewed variables, including sCD93, were 
log transformed for further statistical analyses. Multivariable regression analysis was used to 
identify markers of metabolism or CVD with significant effects on sCD93 levels. Variables 
considered for inclusion were: age and sex (forced into the models), height, weight, BMI, waist 
to hip ratio (WHR), systolic and diastolic blood pressure (SBP and DBP respectively), LDL 
cholesterol, HDL cholesterol, triglycerides (TGs), fasting glucose, C-reactive protein (CRP), 
proinsulin, insulin, HOMA indices, adiponectin, leptin, interleukin 5 (IL-5), current smoking, 
lipid-lowering and anti-hypertensive medication. Multivariable regression, adjusted for 
established CVD risk markers (age, gender, mds1-3, BMI, SBP, HDL, TGs and current 
smoking) (22), was used to assess the effect of sCD93 levels on measures of IMT. Analyses 
were conducted using STATA 11.2 (STATCorp, College Station, TX, USA). 
Statistical analyses: Genetics 
Linear regression analyses assuming an additive genetic model were conducted in PLINK 
(21) to assess the influence of type 2 diabetes risk-associated SNPs on sCD93 levels, 
adjusting for age, sex and population structure (MDS1-3). Genotypes of 52 (of 62 known 
(18)) type 2 diabetes-risk associated SNPs were combined in an unweighted SNP score by 
summing the reported (18) type 2 diabetes risk-increasing alleles for each subject (thus 
representing the total burden of genetically determined type 2 diabetes risk). Only subjects 
without type 2 diabetes and with complete genotyping were included in this analysis. The 
score was tested for influence on levels of sCD93, using a linear regression model as above, 
in STATA 11.2 (STATCorp,Texas, USA).  
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Replication analyses: Stockholm Diabetes Prevention Program (SDPP) 
The SDPP is a prospective study of subjects from the Stockholm area, aged 35-55 years at 
baseline (23). Briefly, blood samples, oral glucose tolerance tests (OGTT), basic clinical 
phenotyping and questionnaires were conducted on participants at baseline and after 8-10 years 
of follow-up. Levels of sCD93 were measured by Mesoscale in baseline samples and in a subset 
of follow-up samples (Online Supplemental Figure 1). Baseline samples were from subjects 
newly diagnosed with normal glucose tolerance (NGT, n=843), pre-diabetes (defined as 
impaired glucose tolerance and/or impaired fasting glucose, n=326) and type 2 diabetes 
(n=113). Follow-up samples from NGT subjects at baseline were also analysed. Some subjects 
remained NGT (n=370), whilst others had progressed to pre-diabetes (n=314) or type 2 diabetes 
(158). Karolinska Institutets Ethics committee approved the study and all subject gave their 
informed consent. ANOVA (adjusted for age and sex) was used to compare levels of sCD93 
between glucose tolerance groups at baseline or after follow-up. T-tests were used to compare 
baseline levels of sCD93 from subjects diagnosed as NGT and prediabetes or T2D at follow-
up. The effect of baseline sCD93 levels on risk of developing prediabetes or T2D was assessed 
using logistic regression, adjusting for age and sex, or age, sex, current smoking, BMI and blood 
pressure medication. Analyses were conducted in STATA 11.2 (STATCorp,Texas, USA). 
Cd93-deficient mice 
The cd93-deficient mouse was generated by the trans-NIH Knock-Out Mouse Project (KOMP) 
and obtained from the KOMP Repository (www.komp.org). Embryonic stem cells were 
generated from C57BL/6N mice and kept on the C57BL/6N background. Breeding of the cd93-
deficient mice did not show a Mendelian ratio, with a very low ratio of homozygous knockout 
mice observed. However, cd93 heterozygous (cd93+/-) mice had half the concentration of 
sCD93 in the periphery compared to their wild-type (cd93+/+) littermates (Supplemental Table 
1), rendering this a relevant model to be used in comparisons to human studies, as humans have 
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varying levels of sCD93 (11), rather than complete absence of sCD93. Therefore, this study 
focuses on cd93+/+ and cd93+/- animals. All mice were bred and kept at the Karolinska Institutet 
animal facility and with 12 hour day/night cycle with food and water ad libutim. All procedures 
were approved by the regional animal ethics authority.  
Characterization cd93-deficient mice 
Mouse scd93 was measured using MesoScale technology with antibodies directed against 
murine cd93 (capture antibody clone 223437, detection antibody BAF1696, R&D systems) 
using EDTA plasma from male mice (N=8 from each genotype) fed on western diet for 16 
weeks. Expression of cd93 on the B cell population (Online Supplemental Table 1) was 
determined by flow cytometry. Single cell suspensions of spleen cells from male mice (N=8 
from each genotype) fed on western diet for 16 weeks were used. Firstly, Fc receptors were 
blocked with anti-FcRII and III (clone 24.G2 in-house preparation). B cells were stained with 
anti-mouse CD45R eFlour450® (clone RA3-6B2 ebioscience) and anti-mouse-CD19 
conjugated with APC-Cy7 (clone 6D5 biolegend). The percent of IgG and IgM positive B cells 
was determined by using anti-mouse IgG conjugated with FITC (Biolegend Poly4060) and anti-
mouse-IgM conjugated with APC (Biolegend RMM-1). Expression of cd93 on B cells was 
determined by anti-mouse cd93 conjugated with PE (Biolegend clone AA4.1) on Beckman 
Coulter Gallios™ flow cytometer. The percent of iNKT cells in the liver was determined using 
the previously published method (10) with the exception that a violet viability dye (Live/Dead 
Life technologies) was included, using the Beckman Coulter Gallios™ flow cytometer. 
Tissue collection and assessment of atherosclerotic lesions in mice (apoe-/-cd93+/+ and apoe-/-
cd93+/-). 
For atherosclerosis studies, mice were crossed into apoe-deficient (apoe-/-) mice (originally 
from Jackson Laboratory) and backcrossed 6 generations to C57BL/6N. Homozygous for apoe 
deficiency mice, with 2 or 1 copies of the cd93 gene (apoe-/-cd93+/+ and apoe-/-cd93+/- 
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respectively) were fed a normal rodent diet for 32 weeks, at which point blood was sampled via 
cardiac puncture. Plasma samples (EDTA) were stored at -80⁰C. Organs were perfused with 
sterile PBS and the descending thoracic aorta was collected into 4% paraformaldehyde. The 
thoracic aorta was pinned onto a paraffin bed and en face lipid content was determined by 
staining with Sudan IV (Sigma-Aldrich). Images were captured using a DC480 camera 
connected to a MZ6 stereomicroscope (both from Leica). Quantification of the area of all the 
plaques in a given aortic arch were summed and expressed as the percentage of the total surface 
area of the aorta using ImageJ software (NIH).  
Metabolic studies of mice (cd93+/+ and cd93+/-) 
For metabolic studies, cd93-deficient mice were fed a western diet (SDS custom diet: 21% fat 
0.2% cholesterol mixed in standard CRM (p) maintenance diet,) for 16 weeks. Glucose and 
insulin tolerance tests were conducted. After 4 hours of fasting, a bolus of glucose (1g/kg for 
glucose tolerance test) or insulin (0.75 U/kg for insulin tolerance test) was given by intra-
peritoneal injection. Blood was sampled from the tail vein at 15, 30, 60, 120 minutes.  
Pancreatic morphology in the cd93-deficient mouse model (cd93+/+ vs cd93+/-) 
Differences in pancreas morphology between genotypes were assessed by immuno-
histochemistry (IHC). Mice were fed a western diet for 16 weeks prior to removal of pancreas. 
Embedding and sectioning of the pancreas as well as rehydration and dehydration of sections 
were conducted as per standard protocols. Four pancreases were analysed per genotype. To 
assess presence and location of insulin, cd93 and von Willebrand Factor (vWF), sections were 
boiled for 20 minutes in Diva Decloaker (Biocare Medical) and sections were treated with 3% 
hydrogen peroxidase before blocking in 5% goat serum in 1% bovine serum albumin. Serial 
sections were stained using antibodies against insulin (guinea pig anti-insulin, Abcam), vWF 
(rabbit anti-vWF, Abcam) and cd93 (rat anti-cd93, R&D). Of note, the anti-cd93 antibody 
targets an extracellular epitope, thus is able to detect cell surface-attached, as well as soluble, 
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cd93. After overnight incubation at 4⁰C, sections were incubated with biotinylated secondary 
antibodies (goat anti-guinea pig, Abcam; goat anti-rabbit; and rabbit anti-rat, Vector 
Laboratories respectively) for 1hr at room temperature. Peroxidase-avidin/biotin complex was 
achieved using Vectastain ABC Elite kit (Vector Laboratories) and detected using Novo Red 
(Vector Laboratories) as per manufacturer’s directions and counterstained with haematoxylin. 
The numbers of islets were counted in parallel by 2 researchers, using 3-5 haematoxylin and 
eosin-stained sections. The size of insulin-stained islets was measured using ImageJ software 
(NIH). The number of vWF-positive and total islets was counted and a percent of positive islet 
staining calculated (number vWF positive islets / total number islets and multiplied by 100). 
The pancreas from one cd93-/- mouse also fed on western diet for 16 weeks was included to 
confirm specificity of anti-cd93 staining. 
Blood vessel integrity (cd93+/+ vs cd93+/-) 
An in vivo blood vessel permeability assay was used by i.v. injection of 0.5% Evans blue into 
anesthetised 4 week old male mice. After 30min, mice were euthanized and perfused with PBS. 
After collection, the pancreases were treated with 50% trichloroacetic acid at a 1:4 ratio 
(ug/mL) and homogenised using Bio-Gen Pro200 (Pro Scientific) for 30 seconds. The amount 
of Evans blue was determined as previously published (24) and detected using GlowMax Multi 
with fluorescence 625/660-720 (Promega).  
Peripheral markers of endothelial damage (cd93+/+ vs cd93+/-) 
Soluble E-selectin and vWF A2 were measured in the plasma of mice fed either a western diet 
of chow diet for 16 weeks. E-selectin was measured using Mesoscale and the DuoKit for E-
selectin (R&D Systems, Minneapolis, MN) with addition of SULFO-TAG labelled 
Streptavidin. vWF A2 was measured using SimpleStep Elisa kit from Abcam as per 
manufacturer’s directions. 
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Statistical analysis of murine data 
Students T-test was used to determine statistical significance between two groups. Differences 
between more than two groups were assessed by one-way ANOVA with post-hoc analysis using 
Tukey’s multiple comparison test. When analysing repeated glucose metabolism 
measurements, a 2-way ANOVA repeated measurements test was used to establish significance 
with post-hoc analysis using Sidak’s multiple comparisons test. PRISM (Graphpad Software, 
San Diego, USA) was used for ANOVA procedures. 
Analysis of sCD93 release from endothelial cells 
To assess the impact of diabetes-relevant conditions on sCD93 release, the human carotid 
endothelial cells (HCtAEC, in complete endothelial cell growth media (Cell Applications)) and 
human endothelial hybrid cell (EA.Hy 926, ATCC, in RPMI, 10% foetal calf serum and 1% 
Penicillin and Streptomycin (Sigma-Aldrich)) were expanded in flasks coated with gelatin 
(Sigma-Aldrich). During passage 5, cells were seeded onto gelatin-coated 48 well plates. After 
overnight incubation with glucose-free DMEM (Sigma-Aldrich), HCtAEC were supplemented 
with 1% Heparin (Sigma-Aldrich), 0.5% endothelial cell growth supplement (Sigma-Aldrich) 
and both HCtAEC and EA.Hy were supplemented with 10% foetal bovine serum and 1% 
Penicillin and Streptomycin. Cells were then stimulated with or without 50nM Phorbol 12-
myristate 13-acetate (PMA) or 50ug/mL lipopolysaccharide (LPS) in 5 or 30mM Glucose 
(Braun). sCD93 was measured as above.  
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Results 
Plasma levels of sCD93 in IMPROVE 
In IMPROVE, latitude was the strongest independent predictor of IMT (17). No significant 
association was observed between sCD93 and latitude (p=0.942). Consistent with previous 
reports (11), there was no significant difference between men and women (mean±sd: 
162±42ng/mL vs 163±45ng/mL, p=0.3833). Levels of sCD93 were significantly lower in 
subjects with type 2 diabetes (157±40ng/mL) compared to those without (164±45ng/mL, 
p<0.0001). Thus, the cohort was stratified for diabetes status as this is likely to impact upon 
further analysis of IMT or other CVD risk factors. 
sCD93 levels and metabolic or cardiovascular risk markers  
In the subjects without diabetes, sCD93 correlated with age, height, and metabolic markers 
(BMI, insulin, HOMA indices, vitamin D and adiponectin; Table 2). Consistent with lower 
levels being associated with poor metabolic control, sCD93 was positively correlated with 
adiponectin and vitamin D, but inversely with BMI, insulin and HOMA. The association 
between sCD93 and lipids was confounded by lipid-lowering medication (Table 2). In lipid-
lowering-naïve subjects, sCD93 levels were associated with an advantageous metabolic profile, 
i.e positively with HDL levels and negatively with TGs. A negative correlation was observed 
between sCD93 levels and SBP, however this association was lost when analysing subjects 
without anti-hypertensive medication. Associations with metabolic variables remained 
significant after adjustment for age and sex (Online Supplemental Table 2). 
sCD93 levels and IMT in IMPROVE 
As cardiovascular risk factors have a large impact on IMT measures (16; 17), these parameters 
were considered for inclusion in multiple regression models. Proinsulin and insulin 
measurements were omitted as they are not informative in subjects with diabetes (due to 
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influence of medication and pathology). Diabetes-stratified multiple regression analysis gave 
rise to 3 models: A) age and sex. B) with variables significant in both subjects with and without 
type 2 diabetes, where DBP, TGs, creatinine and current smoking were added to model A. C) 
further inclusion of variables significant in one stratum (LDL, IL5, adiponectin and SBP). 
sCD93 were not associated with any baseline or progression measures of IMT in subjects with 
or without type 2 diabetes, when adjusting for age and sex (Supplemental Table 3), nor in the 
regression models adjusting for established CVD risk markers (data not shown). We could 
exclude lack of power as a reason for failing to detect an association (assuming an effect size 
of ≥0.009 gave power =0.99 for subjects without type 2 diabetes and 0.81 for the subjects with 
type 2 diabetes). Thus we conclude that sCD93 levels do not influence on IMT.  
Type 2 diabetes risk-associated SNPs and sCD93 levels 
A Mendelian randomisation experiment was conducted to assess whether reduced sCD93 levels 
are a consequence or possible cause of type 2 diabetes. If reduced sCD93 levels are a 
consequence of diabetes-related processes and/or susceptibility, then genetic variants which 
influence risk of type 2 diabetes would be expected to influence sCD93 levels. Genotypes of 
53 (of 62 known (18)) type 2 diabetes risk-associated SNPs were available for the IMPROVE 
cohort and were analysed for association with sCD93 levels (adjusting for age, sex and 
population structure in subjects without diabetes). Individually, no SNP met the Bonferroni-
corrected p value for significance (p<9.43E-4, Supplemental Table 4), nor was there any 
correlation with sCD93 levels for SNPs combined in an un-weighted SNP score (Spearmans 
rank rho=0.0045, p=0.8248). These findings indicate that genetic susceptibility to type 2 
diabetes is unlikely to be a cause of reduced CD93 levels; hence, it is possible that reduced 
sCD93 levels precede development of type 2 diabetes.  
Soluble CD93 levels in the prospective SDPP cohort 
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In order to assess whether the multiple metabolic aberrations which characterize IMPROVE 
affect the results presented, the prospective SDPP cohort, specifically designed to assess 
potential biomarkers of type 2 diabetes, was investigated.  Baseline and follow-up features are 
presented in Supplemental Table 5 and Table 3, respectively. Baseline levels of sCD93 did 
not differ across glucose tolerance groups: NGT 163±44ng/mL, prediabetes 158±44ng/mL 
and type 2 diabetes 158±41ng/mL (ANOVA p=0.23, adjustment for age and sex). Similarly, 
no significant difference was found between follow-up levels of NGT, pre-diabetes or type 2 
diabetes (153±42, 154±51 and 154±48 ng/mL, respectively). To assess whether baseline 
sCD93 levels influenced progression to prediabetes or to type 2 diabetes over the time, 
baseline levels were compared between subjects (all NGT at baseline) who were diagnosed as 
NGT, prediabetes or type 2 diabetes at follow-up. Subjects who remained NGT at follow-up 
had significantly higher baseline levels of sCD93 than those who progressed from NGT to 
type 2 diabetes during follow-up (166±44ng/mL vs 158±45ng/mL respectively, T-test 
p=0.016). A similar non-significant trend of higher baseline sCD93 levels was observed in 
subjects who remained NGT at follow-up compared to those who progressed to pre-diabetes 
during follow-up (166±44ng/mL vs 161±44ng/mL, respectively, p=0.058). Logistic 
regression demonstrated that baseline sCD93 levels were significantly associated with 
progression to poor metabolic control (prediabetes or T2D, beta -0.612, se 0.272, p=0.024) 
but not to T2D specifically (beta -0.573, se 0.346, p=0.098), and this was independent of 
current smoking, blood pressure medication and BMI (beta -0.894, se 0.298, p=0.003). 
However, inclusion of sCD93 levels in the model did not provide additional benefits (area 
under ROC curve 0.73 irrespective of inclusion of sCD93). 
These results support the hypothesis that reduced sCD93 levels occur before onset of type 2 
diabetes.  
Cd93-deficient mouse model 
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A cd93-deficient mouse model has previously been described (6), where there was no gross 
phenotypic abnormality. However, mice demonstrated reduced phagocytic activity (6), 
defective maturation of B cells and iNKT cells (23; 25) and altered vascular permeability in 
glioma (9). These mice lack only exon 1 of the cd93 gene and had a mixed genetic background, 
(129/sv embryonic stem cells crossed to C57BL/6J). In contrast, our strategy maintained a 
genetically pure strain, namely C57BL6/N, with the entire cd93 gene being deleted. This cd93-
deficient mouse model again showed no gross phenotypic defect, however there was partial 
lethality. Importantly, mice carrying one cd93 gene (cd93+/-) had approximately half the 
concentration of circulating scd93 compared to wild type mice (cd93+/+, 104±18 vs 254±63 
ng/mL respectively, p=0.008, Supplemental Table 1). Compared to cd93+/+, cd93+/- mice 
showed no difference in mature B cell populations (determined by percentage IgG or IgM 
positive B cells) or iNKT cells (Supplemental Table 1). Therefore, these mice were appropriate 
for our studies aimed at investigating whether reduced levels of scd93 influence development 
of atherosclerosis and type 2 diabetes. 
Atherosclerosis in apoe-/-cd93+/+ vs apoe-/-cd93+/- mice 
To investigate the impact of CD93 on atherosclerosis, the cd93-deficient mouse model was 
crossed with the apoe-deficient (apoe-/-) mice, commonly used to study atherosclerosis. Apoe-/-
cd93+/+ and apoe-/-cd93+/- mice were fed a chow diet until being sacrificed at 32 weeks. Whilst 
atherosclerotic lesions were visible in the descending aorta, there was no difference between 
apoe-/-cd93+/+ and apoe-/-cd93+/- mice regarding the lesion area observed (Figure 1). Thus, these 
data are consistent with the human findings that scd93 levels do not influence IMT.  
Metabolic characteristics of cd93+/+ vs cd93+/ mice 
To mirror the human metabolic findings, we investigated whether mice with reduced sCD93 
levels had impaired glucose metabolism. When fed a chow diet, both genotypes demonstrated 
a similar rate of glucose clearance, however cd93+/- male mice had higher basal level of glucose 
17 
 
compared with cd93+/+ (mean ± sem: 187.4 ± 13.6 mg/dL vs 161.9 ± 4.2 mg/dL respectively, 
after 4 hour fasting, Figure 21). Female mice demonstrated no significant difference (mean ± 
sem: 137.5 ± 4.7 mg/dL vs 137.4 ± 5.7 mg/dL, after 4 hour fasting, Online Supplement Figure 
2). However, when fed a western diet (21% fat, 0.2% cholesterol), male cd93+/- mice 
demonstrated impaired clearance of glucose and reduced sensitivity to insulin compared to 
cd93+/+ mice, which was not due to a difference in weight (Figure 2). This was not seen in 
female mice (Online Supplement Figure 2). Levels of fasting insulin and biomarkers of 
metabolic dysregulation (leptin, glucagon, resistin and GLP-1) were measured and compared 
between cd93+/- and cd93+/+ mice (Table 4). Whilst not statistically different, a trend was 
observed whereby cd93+/- mice had increased levels of insulin and leptin levels compared to 
cd93+/+ mice and were more insulin resistant (as measured by HOMA-IR).  
Assessment of pancreas morphology (cd93+/+ vs cd93+/-) 
The number and the average size of islets did not differ between cd93+/+ and cd93+/- mice (21.7 
vs 24.1, p=0.34 and 595 vs 622 pixels, p=0.42, respectively). Insulin staining was visible in 
islets in all genotypes, however some interstitial insulin staining was apparent in sections from 
the cd93+/- mice (Figure 3, top panel). As expected, vWF staining was restricted to endothelium 
in all genotypes (Figure 3, middle panel). In cd93+/+ mice, cd93 demonstrated endothelial 
staining (as expected with cell surface-attached cd93; Figure 3, bottom panel) similar to that of 
vWF. Diffuse cd93 staining was also observed in the islets. Whilst this could reflect a 
previously unappreciated expression of cd93 by beta cells, we believe that it is more likely that 
the diffuse staining reflects the scd93 released from the endothelial cells. In cd93+/- mice, the 
endothelial cd93 staining was less obvious, but the diffuse cd93 staining was clearly visible. 
However, in the pancreas obtained from a cd93-/- mouse, no cd93 staining was observed. 
Interestingly, cd93+/- mice had a trend (p=0.08) of decreased percentage of vWF positive islets 
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compared to cd93+/+ mice, indicating the presence of endothelial disturbances in western diet 
fed cd93+/- mice (Figure 4A). 
Pancreatic blood vessel integrity 
Given the role of cd93 in vessel leakage (9), and the interstitial insulin staining in cd93+/- 
mice, we performed an in vivo blood vessel permeability assay using Evans blue. Under 
physiologic conditions the endothelium is impermeable to albumin, so Evans blue-bound 
albumin remains confined within blood vessels. Presence of Evans blue within a tissue after 
perfusion with PBS indicates leakage out of blood vessels into the interstitial space. 
Interestingly, young cd93+/- mice had an increase in Evans blue compared to cd93+/+ 
littermates (Figure 4B). The finding that higher levels of Evans blue were detected in cd93+/- 
than cd93+/+ mice provided confirmation that the (albeit weak) interstitial insulin staining in 
the pancreas of cd93+/- mice was not merely an artefact. Thus, lacking cd93 even at a young 
age results in leaky vessels, however, neither young animals nor mice fed on rodent chow 
displayed a diabetes phenotype. Therefore, we questioned whether after metabolic stress of 
western diet there was signs of endothelial damage in plasma, indicated by soluble e-selectin 
and vWF A2. Indeed, cd93+/- mice fed on a western diet demonstrated an increase in both 
endothelial damage markers compared with cd93+/+ (Figure 4C and D), indicating endothelial 
damage in the western diet-fed cd93+/- mice.  
Influence of high glucose levels on release of sCD93 from endothelial cells 
As diffuse cd93 staining was observed in islets and as metabolic regulation in mice was 
impaired after dietary stress, we investigated whether the release of sCD93 (by known stimuli) 
might be influenced by hyper-glycaemia, mimicking the prediabetes state. Glucose levels did 
not influence the release of sCD93 from primary HCtAEC under basal (media) or LPS-
stimulated conditions (Online Supplemental Figure 32A), however hyper-glycaemia (30mM 
glucose) reduced PMA-stimulated release of sCD93 compared to normo-glycaemia (5mM 
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glucose). This experiment was repeated with the EA.Hy 926 cell line, with comparable results 
(Online Supplemental Figure 3B). 
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Discussion 
The main objective of this study was to elucidate whether sCD93 plays a role in metabolic or 
cardiovascular disease. Our results refute sCD93 as an important factor in the early vascular 
changes indicative of atherosclerosis, however they do provide solid evidence for a role of 
sCD93 in glucometabolic regulation and a starting point for understanding the role of CD93 in 
these diseases. 
The most striking result from the present study is the finding that reduced levels of sCD93 were 
associated with metabolic dysregulation. In addition, we show that: i) lower sCD93 levels were 
observed in high CVD risk subjects with type 2 diabetes than those without; ii) insulin-related 
processes were associated with sCD93 levels in subjects without diabetes; iii) lower levels of 
sCD93 were not due to genetic susceptibility to type 2 diabetes; iv) lower sCD93 levels precede 
development of type 2 diabetes; v) dietary stress in a cd93-deficient mouse model caused 
impaired metabolic regulation and increased endothelial damage; vi) cd93 (both cell surface-
bound and soluble) was detected in islets; vii) hyper-glycaemia impaired the release of sCD93 
by specific stimuli. The lack of association between sCD93 levels and early atherosclerosis 
measures is consistent between human and mouse. 
Thus, we propose that CD93 expression and sCD93 release in pancreatic islets are components 
of stress responses and are is important for endothelial integrity and thereby metabolic control. 
CD93-deficiency leads to leaky blood vessels, which under normal metabolic conditions is 
tolerated or compensated for. However, when stressed (inflammatory or metabolic), release of 
sCD93 is further impaired, possibly leading to endothelial damage. Leaky vessels and 
endothelial damage would permit insulin diffusion into the interstitial space leads to sub-
optimal insulin delivery to distal tissues. These results are the first direct evidence for the 
recently proposed role for CD93 in type 2 diabetes (12).  
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In view of previous publications on CD93, it should be noted that there was no evidence to 
suggest that changes in iNKT cells were responsible for the effects reported here, in contrast to 
previous reports (10). In addition, 2 SNPs associated with sCD93 levels in control subjects have 
been described (11). No associations were observed between these SNPs and sCD93 levels or 
insulin sensitivity (Supplementary Table 6) in IMPROVE, nor do they demonstrate any 
association with type 2 diabetes (DIAGRAM consortium, n=100,589, rs2749812 p=0.940, 
rs3746731 p=0.870 (18)). Whilst IMPROVE is the largest cohort to date with data on sCD93 
levels, this cohort is not metabolically uniform, in contrast to the myocardial infarction cases 
and healthy controls (11), where few subjects were on lipid-lowering or anti-hypertensive 
medication and very few subjects had type 2 diabetes. Therefore comparisons between the 
Mälarstig (11) and IMPROVE data should be approached with caution. We admit that the size 
of the SDPP replication study is limited, however, the use of OGTT to define glucose control 
categories and the length of follow-up compensate for the restricted sample size. A further 
caveat is that the murine model demonstrated a sex difference which was not seen in the clinical 
data. The murine studies were conducted in mice of reproductive age, thus it is plausible that 
age-related differences in hormones might contribute to this discrepancy. Women of 
IMPROVE were all in post-menopausal, thus this effect was not seen. The SDPP cohort was 
younger so it cannot be assumed that female participants in SDPP are post-menopausal, 
however the size of the cohort precluded assessment of sex-specific effects.  
Previously, release of sCD93, has been implicated as a response to stressors such as 
inflammatory, immune and angiogenic mediators.  Our demonstration of clear cd93 staining in 
pancreatic islets is novel and might reflect a protective function, whereby a deficiency in cd93 
results in morphological and physiological changes in the pancreas. Furthermore, the in vitro 
studies showing that sCD93 was not released from endothelial cells as efficiently under hyper-
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glycaemia fits with the documented downward spiral of glycaemic control characteristic of type 
2 diabetes progression. 
Differences in sCD93 levels between subjects with and without diabetes are subtle; therefore it 
is unlikely that measurement of sCD93 levels would have clinical utility as biomarker. 
However, given that this molecule might mediate both inflammatory and metabolic pathways, 
further investigation and understanding of CD93 functions is warranted and might provide 
opportunities for future preventative strategies. Having established the cd93-deficient mouse 
model and confirmed the human relevance, we are able to continue to conduct a deeper 
functional evaluation of cd93. 
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Table 1: IMPROVE cohort characteristics 
    without diabetes type 2 diabetes P 
N 
 
2470 901 
 
Male [%] 1138 [44.7] 533 [57.4] <0.0001 
Age (years) 64.2 (5.4) 64.2 (5.6) 0.8246 
Height (m) 1.67 (0.09) 1.69 (0.09) <0.0001 
BMI (kg/m2) 26.6 (3.9) 29.2 (4.6) <0.0001 
WHR 0.91 (0.08) 0.95 (0.09) <0.0001 
SBP 141 (19) 145 (18) <0.0001 
DBP 82 (10) 82 (10) 0.3524 
LDL (mmol/L) 3.71 (0.97) 3.07 (0.95) <0.0001 
HDL (mmol/L)* 1.31 (0.36) 1.14 (0.33) <0.0001 
Triglycerides (mmol/L)* 1.47 (0.90) 1.91 (1.82) <0.0001 
Fasting glucose (mmol/L)* 5.29 (0.67) 7.71 (2.18) <0.0001 
C reactive protein (mmol/L)* 2.89 (6.16) 3.20 (4.22) 0.0001 
CD93 (ng/mL)* 164 (45) 157 (40) <0.0001 
Fasting proinsulin (pmol/L)* 6.03 (6.26) 10.5 (8.88) <0.0001 
Fasting insulin (pmol/L)* 44.4 (61.5) 66.5 (88.4) <0.0001 
HOMA B* 68.9 (54.3) 50.8 (50.8) <0.0001 
HOMA IR* 0.83 (1.09) 1.33 (1.66) <0.0001 
Uric acid (mmol/L)* 309 (70) 333 (76) <0.0001 
Creatinine (mmol/L)* 80.3 (17.7) 82.8 (17.7) <0.0001 
Vitamin D (nmol/L)* 50.7 (21.5) 48.2 (20.2) 0.963 
Adiponectin (ug/mL)* 14.2 (9.9) 9.43 (7.19) <0.0001 
Leptin (ng/mL)* 20.0 (17.0) 21.6 (17.4) 0.0138 
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IL-5 (pg/mL)* 0.67 (1.82) 0.86 (3.50) <0.0001 
Pack years 9.84 (16.3) 14.1 (18.6) <0.0001 
Current smoking [%] 381 [15.0] 143 [15.4] 0.7483 
Lipid-lowering medication [%] 1268 [49.8] 449 [48.6] 0.542 
Anti-hypertensive medication [%] 1397 [54.8] 604 [65.0] <0.0001 
B
as
el
in
e 
CC-IMTmean* 0.738 (0.141) 0.758 (0.145) 0.0001 
BIF-IMTmean* 1.131 (0.396) 1.190 (0.429) 0.0002 
IMTmean* 0.880 (0.196) 0.918 (0.206) <0.0001 
CC-IMTmax* 1.185 (0.196) 1.225 (0.412) 0.0035 
BIF-IMTmax* 1.840 (0.750) 1.954 (0.829) 0.0004 
IMTmax* 1.998 (0.792) 2.140 (0.862) <0.0001 
IMTmean-max* 1.239 (0.292) 1.290 (0.312) <0.0001 
P
ro
g
re
ss
io
n
 
CC-IMTmean 0.008 (0.025) 0.011 (0.034) 0.0031 
BIF-IMTmean 0.032 (0.070) 0.040 (0.087) 0.0134 
IMTmean 0.018 (0.030) 0.022 (0.035) 0.0007 
CC-IMTmax 0.013 (0.087) 0.019 (0.113) 0.1385 
BIF-IMTmax 0.047 (0.153) 0.058 (0.178) 0.0700 
IMTmax 0.040 (0.157) 0.056 (0.178) 0.0145 
IMTmean-max 0.162 (0.140) 0.188 (0.155) 0.0482 
fastest_progression 0.024 (0.051) 0.028 (0.054) <0.0001 
Where: values are presented as mean (standard deviation) for continuous measures and n 
[%] for categorical measures. T2D was defined as diagnosis, anti-diabetic medication or 
fasting glucose >=7mmol/L; Vitamin D, adjusted for season of blood sampling; all IMT 
measured in mm. P-value as determined by T-test. * log10 transformed prior to analysis. 
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Table 2: Spearmans rank correlation coefficients between sCD93 and cardiovascular risk 
markers 
  without diabetes type 2 diabetes 
  Rho P Rho P 
Sex -0.001 0.9671 -0.045 0.1882 
Age (years) 0.080 0.0001 0.166 <0.0001 
Height (m) -0.063 0.0022 -0.054 0.1163 
BMI (kg/m2) -0.073 0.0003 -0.042 0.2199 
WHR 0.023 0.2672 0.007 0.8511 
SBP (mmHg) -0.033 0.1067 -0.099 0.0042 
SBP (mmHg)* -0.023 0.4501 0.038 0.5048 
DBP (mmHg) -0.020 0.3319 -0.016 0.6428 
DBP (mmHg)* -0.050 0.0940 -0.003 0.9619 
LDL cholesterol (mmol/L) 0.042 0.0422 -0.028 0.4210 
LDL cholesterol (mmol/L)# 0.006 0.8265 0.048 0.3165 
HDL cholesterol (mmol/L) -0.073 0.0003 -0.081 0.0195 
HDL cholesterol (mmol/L)# 0.056 0.0343 -0.019 0.6872 
Triglycerides (mmol/L) -0.051 0.0131 -0.010 0.7663 
Triglycerides (mmol/L)# -0.098 0.0002 -0.074 0.1106 
Fasting glucose (mmol/L) -0.014 0.5101  0.020  0.5704 
C reactive protein (mmol/L) -0.014 0.5101 0.020 0.5704 
Current smoking 0.022 0.2833 -0.004 0.9027 
Lipid lowering medication -0.024 0.2455 0.000 0.9915 
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Anti-hypertensive medication -0.025 0.2191 0.033 0.3467 
fasting proinsulin (pmol/L) -0.025 0.2223 -0.024 0.4826 
fasting insulin (pmol/L) -0.078 0.0001 -0.007 0.8293 
HOMA B -0.054 0.0076 0.021 0.5333 
HOMA IR -0.080 0.0001 -0.011 0.7263 
Uric Acid (micromol/L) 0.019 0.3567 0.023 0.5073 
Creatinine (micromol/L) 0.173 <0.0001 0.237 <0.0001 
Vitamin D (nmol/L) 0.067 0.0009 0.032 0.3310 
Adiponectin (ug/mL) 0.063 0.0022 0.028 0.4159 
Leptin (ng/mL) -0.025 0.2197 0.000 0.9932 
IL-5 (pg/mL) 0.091 <0.0001 0.034 0.3060 
FRS 0.022 0.2719 0.103 0.0019 
Where: T2D was defined as diagnosis, anti-diabetic medication or fasting glucose 
>=7mmol/L;* subjects not on Anti-hypertensive medication (n= 1120 and 316 for subjects 
without diabetes and with type 2 diabetes respectively); # subjects not on lipid lowering 
medication (n= 1426 and 462 for subjects without diabetes and with type 2 diabetes 
respectively); FRS, Framingham risk score; Vitamin D, adjusted for season of blood 
sampling.  
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Table 3: Characteristics of the SDPP subjects diagnosed at baseline as NGT  
   Follow up diagnosis 
without 
diabetes prediabetes 
type 2 
diabetes 
ANOV
A p 
Nn* 370 314 158 
 
Mmale [%] 200 [54] 179 [57] 110 [69] 0.0019 
B
as
el
in
e 
Age (years) 47.3 (4.7) 48.2 (4.4) 48.2 (4.6) 0.0102 
Height (m) 1.73 (0.09) 1.72 (0.09) 1.74 (0.09) 0.1294 
Weight (kg) 74.9 (12.4) 81.8 (14.1) 85.6 (15.2) <0.0001 
BMI (kg/m2) 24.9 (3.2) 27.6 (4.1) 28.4 (4.7) <0.0001 
WHR 0.84 (0.07) 0.87 (0.07) 0.90 (0.06) <0.0001 
SBP 121 (14) 128 (15) 130 (15) <0.0001 
DBP 76 (9) 80 (9) 81 (9) <0.0001 
Fasting glucose 
(mmol/L) 4.6 0 (0.49) 4.94 (0.50) 5.06 (0.56) <0.0001 
Fasting insulin (mU/L) 14.2 (6.3) 17.5 (9.0) 21.2 (10.2) <0.0001 
sCD93 (ng/mL) 166 (44) 161 (44) 158 (45) 0.0700 
scCurrent smokers [%] 89 [22.2] 105 [29.2] 63 [36.8] 0.0012 
BP treatment [%] 19 [4.8] 38 [10.6] 18 [10.6] 0.0055 
F
o
ll
o
w
u
p
 
Follow-up time 9.1 (1.3) 9.2 (1.2) 9.5 (1.2) 0.0025 
Age (years) 56.5 (4.8) 57.4 (4.5) 57.7 (4.7) 0.0021 
Height (m) 1.72 (0.09) 1.71 (0.09) 1.73 (0.09) 0.0727 
Weight (kg) 77.1 (13.3) 86.5 (15.9) 91.0 (18.2) <0.0001 
BMI (kg/m2) 25.9 (3.4) 29.4 (4.8) 30.3 (5.8) <0.0001 
WHR 0.88 (0.06) 0.91 (0.06) 0.94 (0.07) <0.0001 
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SBP 133 (17) 143 (17) 144 (18) <0.0001 
DBP 82 (10) 87 (10) 87 (11) <0.0001 
Fasting glucose 
(mmol/L) 4.86 (0.46) 5.72 (0.68) 7.35 (2.18) <0.0001 
Fasting insulin (mU/L) 14.6 (6.0) 21.2 (11.9) 26.6 (13.2) <0.0001 
sCD93 (ng/mL) 153 (42) 154 (51) 154 (48) 0.9654 
delta sCD93 13 (46) 7 (52) 4 (55) 0.0814 
Cscurrent smokers [%] 61 [15.3] 73 [20.3] 34 [20.0] 0.1486 
T2D treatment [%] 0 0 39 [22.8] <0.0001 
BP treatment [%] 64 [16.0] 133 [36.9] 72 [42.1] <0.0001 
Where: values are presented as mean (standard deviation) for continuous measures and n 
[%] for categorical measures; Prediabetes defined as impaired glucose tolerance and/or 
impaired fasting glucose;* smallest n for any variable; delta sCD93, baseline sCD93 – 
follow-up sCD93. 
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Table 4: Peripherial fasting levels of diabetes relevant analytes 
 
cd93+/- cd93+/+ p-value 
Glucose (nmol/L) 12.6 11.1 0.03 
Insulin (ng/mL) 17.4 12.6 0.24 
Leptin (ng/mL) 62.2 51.5 0.24 
Resistin (ng/mL) 164 183 0.30 
Glucagon (ng/mL) 0.09 0.07 0.50 
GLP-1 (ng/mL) 0.03 0.01 0.26 
Homa-IR* 0.25 0.16 0.15 
Total cholesterol (mg/dL) 442 433 0.86 
Triglycerides (mg/dL) 138 139 0.89 
where: HOMA-IR* was calculated by G0 x I0 /22.5 where I0 is fasting blood insulin 
(μU/mL) and G0 fasting blood glucose (mmol/L) 
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Figure legends 
Figure 1:  Representative image of the descending aorta stained with sudan IV, from A) apoe-/-
cd93+/- and B) apoe-/-cd93+/+ mice. C) Quantification of lesions in the descending aorta of 
female and male apoe-/-cd93+/- (black dots, n=11 (6 male, 5 female)) or apoe-/-cd93+/+ (black 
squares, n=9 (5 male, 4 female)) mice.  
Figure 2: Glucose metabolism of cd93+/- male mice compared to cd93+/+ male mice (black dots 
and black squares respectively). A) Glucose tolerance test of cd93+/- and cd93+/+ male mice 
(n=10-13), aged 4 months, before given a western diet. B) Weight of cd93+/- and cd93+/+ male 
mice (n=9-12 respectively), after 16 weeks of western diet. C) Glucose tolerance test of cd93+/- 
and cd93+/+ male mice (n=9-12 respectively), after 16 weeks of western diet. D) Insulin 
tolerance test of cd93+/- and cd93+/+ male mice (n=9-11 respectively), after 16 weeks of western 
diet. Repeated measures 2 way ANOVA showed statistical significance for C and D with ** 
indicating p≤ 0.01 or * indicating p≤ 0.05 statistical significance at a particular time point/s 
between genotypes using post-hoc analysis of Sidak’s multiple comparisons test, error bar 
SEM. 
Figure 3: Immunohistochemistry of pancreas sections demonstrating the location of insulin, 
sCD93 and vWF in mice with 2, 1 or 0 copies of the cd93 gene (cd93+/+, cd93+/- and cd93-/- 
respectively). 
Figure 4: Vascular integrity and endothelial damage in cd93+/+ and cd93+/- mice. A) Percentage 
of vWF positive islets in pancreas from mice fed 16 weeks on western diet (4 of each genotype). 
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B) Quantification of Evans blue in pancreas in cd93+/- and cd93+/+ mice (4 of each genotype, 
black and white bars respectively), * p≤ 0.05 Student’s T-test. C) Plasma levels of soluble vWF 
A2 in cd93+/- and cd93+/+ and mice and fed 16 weeks on western diet (black and white bars 
respectively) or on chow diet (dark and light hashed bars respectively), n=9-11 per genotype, * 
p≤ 0.05 one way ANOVA, using Tukey’s multiple comparison test between genotypes and diet. 
D) Plasma levels of e-selectin in cd93+/- and cd93+/+ and mice and fed 16 weeks on western diet 
(black and white bars respectively) or on chow diet (dark and light hashed bars respectively), 
n=9-11 per genotype, * p≤ 0.05 Student’s T-test. All error bars indicate SEM.  
 
 
 
